Pfizer (NYSE: PFE) reported that elranatamab (Elrexfio) met its primary endpoint in the Phase III MagnetisMM-5 trial, demonstrating a statistically significant improvement in progression-free survival versus standard-of-care daratumumab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who had received at least one prior line of therapy. The readout positions Elrexfio as a potential earlier-line option in a disease where most patients cycle through multiple regimens before exhausting available treatments.
The MagnetisMM-5 trial is an open-label, multicenter, randomized Phase III study that enrolled 497 patients across 26 countries with relapsed or refractory multiple myeloma who had previously received lenalidomide and a proteasome inhibitor.
Pfizer disclosed that PFS, assessed by blinded independent central review, exceeded the pre-specified interim hazard ratio threshold for efficacy, with most elranatamab-treated patients remaining progression-free at the time of the analysis. The company did not release a numerical hazard ratio, median PFS values, or response rates in the topline announcement, describing the improvement as clinically meaningful without quantifying the magnitude. Overall survival, a key secondary endpoint, was not yet mature and the trial continues. Safety was consistent with the established elranatamab profile, with no new signals identified.
The context for these results matters. Elrexfio currently carries US FDA accelerated approval for adults with RRMM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. In the EU, conditional marketing authorization covers patients after at least three prior therapies. MagnetisMM-5 enrolled patients after as few as one prior line, meaning a positive outcome here could support a substantially earlier label, broadening the eligible population considerably.
Elranatamab is a subcutaneously delivered bispecific antibody that binds B-cell maturation antigen on myeloma cells and CD3 on T cells, redirecting cytotoxic T cells to kill BCMA-expressing tumor cells. The mechanism is shared by two other approved agents in the class: teclistamab (Tecvayli), which received FDA accelerated approval in October 2022, and linvoseltamab (Lynozyfic), approved by the FDA in July 2025. All three are BCMA×CD3 bispecifics administered on step-up dosing schedules designed to mitigate cytokine release syndrome, the class's most clinically prominent toxicity. Cross-trial comparisons are limited by differences in patient populations, prior therapy requirements, and trial designs, meaning the MagnetisMM-5 data cannot be directly interpreted as evidence of superiority over teclistamab or linvoseltamab.